S3 Table. Anticancer drugs included in combination therapy, except docetaxel

	No. of patients (%)
Total number of patients receiving combination chemotherapy	230 (100)
Anticancer drugs	
Trastuzumab	63 (27.4)
Pertuzumab	59 (25.7)
Carboplatin	53 (23.0)
Cisplatin	44 (19.1)
Ramucirumab	2 (0.9)
Atezolizumab	1 (0.4)
Cyclophosphamide	103 (44.8)
Fluorouracil	9 (3.9)
Gemcitabine	2 (0.9)
Doxorubicin	6 (2.6)
Bicalutamide	1 (0.4)